financetom
Business
financetom
/
Business
/
Want to invest in luxury? Choose wine over handbags and scotch
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Want to invest in luxury? Choose wine over handbags and scotch
Sep 24, 2021 11:40 AM

If one is looking to invest in luxury products as an asset class, then wine is the asset that will give the best returns. According to the latest data from Knight Frank’s Luxury Investment Index (Q2 2021), investment-grade wine has seen returns better than previous top investments -- luxury handbags and rare whisky.

“Two assets that have been at the helm of the Knight Frank Luxury Investment Index (KFLII) in recent years -- rare bottles of scotch and Hermés handbags -- have relinquished their places at the top of the index, recording negative 12-month growth. Wine is the front-runner in the 12 months to the end of June 2021 with prices rising 13 percent and 119 percent over a 10-year period,” said Andrew Shirley, editor of Luxury Investment Index at Knight Frank.

“Wine is doing really well, not going crazy but growing nicely. There are no signs of over-exuberance,” explained Wine Owners’ Nick Martin who compiles the data for The Knight Frank Fine Wine Icons Index.

“One market that has been doing well this year is Bordeaux. Burgundy, on the other hand, is taking a bit of a breather.”

Also read: Men, not women, drive luxury goods sales in China

While wine has seen the best returns over a 12-month period, it is far outclassed by other investments over a longer 10-year period. Rare whisky posted returns of 483 percent over 10 years, far higher than the runner-up asset class of collectible cars which had a growth of 122 percent over the same period.

Classic cars and luxury watches were the third and second-best asset classes for 12-month investment periods with price increases of 4 and 5 percent, respectively.

Knight Frank Research compiled the data of the prices from Art Market Research (art, coins, furniture, handbags, jewellery and watches), Fancy Color Research Foundation (coloured diamonds), HAGI (cars), Rare Whisky 101 and Wine Owners.

(Edited by : Shoma Bhattacharjee)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--IEA Nations to Release Record 400 Million Barrels of Oil
--IEA Nations to Release Record 400 Million Barrels of Oil
Mar 11, 2026
10:17 AM EDT, 03/11/2026 (MT Newswires) -- Price: 150.41, Change: +2.28, Percent Change: +1.54 ...
US safety board to hold hearing on two fatal Ford crashes
US safety board to hold hearing on two fatal Ford crashes
Mar 11, 2026
WASHINGTON, March 11 (Reuters) - The National Transportation Safety Board will hold a March 31 hearing to determine the probable cause of two fatal crashes involving Ford Motor's advanced driver assistance system BlueCruise. NTSB Chair Jennifer Homendy told Reuters the board would meet on the crashes later this month. Since 2025, both the NTSB and National Highway Traffic Safety Administration...
Why Is Nauticus Robotics Stock Down 20% Today?
Why Is Nauticus Robotics Stock Down 20% Today?
Mar 11, 2026
Nauticus Robotics Inc ( KITT ) shares are trading lower Wednesday morning after the marine robotics company disclosed a new convertible debt issuance that could add to future share dilution. Here’s what investors need to know. Nauticus Robotics ( KITT ) stock is feeling bearish pressure. What’s pressuring KITT stock? Nauticus Issues $1 Million Convertible Note Due 2026 In a...
What's Going On With Olema Pharmaceuticals Stock On Wednesday?
What's Going On With Olema Pharmaceuticals Stock On Wednesday?
Mar 11, 2026
Olema Pharmaceuticals Inc. ( OLMA ) stock plunged on Monday as the company navigates recent developments in its clinical trials. On Monday, Roche Holdings AG (OTC:RHHBY) released data from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. The study did not meet its primary objective of a statistically significant improvement in progression-free...
Copyright 2023-2026 - www.financetom.com All Rights Reserved